The FDA designated aTyr Pharma�s $LIFE Resolaris for Fast Track review for the treatment of facioscapulohumeral muscular dystrophy (FSHD), an unusual and severe genetic disorder characterized by muscle weakness and wasting. It affects roughly 19,000 Americans every year. There no approved drugs for the ailment. Fast Track designation provides more frequent interactions with the FDA review team and a rolling review of the Biologics License Application (BLA). The company expects to submit results from three Phase 1b/2 studies in December.